[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337660-105":59,"doc-detail-337660-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","subtyping-of-triple-negative-breast-cancers-its-prognostication-and-implications-in-diagnosis-of-breast-origin","Subtyping of triple-negative breast cancers - its prognostication and implications in diagnosis of breast origin","","Triple-negative breast cancer (TNBC) is clinically aggressive and difficult to manage because tumors lack ER, PR, and HER2 and may be challenging to confirm as breast in metastatic disease. Gene-profiling-based TNBC subtyping offers useful clinical information, but laboratory practicality limits routine use. This study assesses immunohistochemistry (IHC) surrogates to classify 123 TNBC cases into four subtypes, evaluate biomarker profiles, and compare prognostic outcomes, including refinement of IM categories by CD8 spatial distribution.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/subtyping-of-triple-negative-breast-cancers-its-prognostication-and-implications-in-diagnosis-of-breast-origin/337660/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/subtyping-of-triple-negative-breast-cancers-its-prognostication-and-implications-in-diagnosis-of-breast-origin/337660.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What TNBC subtypes were evaluated in the study?","Question",{"text":112,"@type":113},"The study classified 123 TNBC cases into luminal androgen receptor (LAR), basal-like immunosuppressive (BLIS), mesenchymal-like (MES), and immunomodulatory (IM). The IM group was further divided into IM-excluded and IM-inflamed using CD8 spatial distribution.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were TNBC subtypes determined in this research?",{"text":117,"@type":113},"TNBC cases were classified using immunohistochemistry (IHC) surrogates based on androgen receptor (AR), CD8, FOXC1, and DCLK1. The work assessed how well this IHC approach captured clinicopathological and biomarker patterns linked to gene-profiling subtypes.",{"name":119,"@type":110,"acceptedAnswer":120},"Which subtype showed the best and poorest outcomes?",{"text":121,"@type":113},"The IM-inflamed subtype had the best outcome, whereas BLIS had significantly poorer survival. The IHC-defined subtypes also showed distinct clinicopathological and biomarker profiles.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337660,1790192831,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","ORIGINAL RESEARCH  \nSubtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin  \nH. Hu1, K. Tong2, J. Y. Tsang2, C. W. Ko2, F. Tam3, T. C. Loong4 & G. M. Tse2 􀀁  \n1Division of Breast Surgery, Department of General Surgery, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Afﬁliated Hospital, Southern University of Science and Technology), Shenzhen, China; 2Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; 3Department of Pathology, Kwong Wah Hospital, Hong Kong; 4Department of Pathology, Tuen Mun Hospital, Hong Kong  \nAvailable online xxx  \nBackground: Triple-negative breast cancer (TNBC) subtyping by gene proﬁling has provided valuable clinical information. Here, we aimed to evaluate the relevance of TNBC subtyping using immunohistochemistry (IHC), which could be a more clinically practical approach, for prognostication and applications in patient management.  \nMethods: A total of 123 TNBC cases were classiﬁed using androgen receptor (AR), CD8, Forkhead box C1 protein (FOXC1), and doublecortin-like kinase 1 (DCLK1) into luminal androgen receptor (LAR), basal-like immunosuppressive (BLIS), mesenchymal-like (MES), and immunomodulatory (IM) subtypes. The IM cases were further divided into the IM-excluded and IM-inﬂamed categories by CD8 spatial distribution. Their clinicopathological and biomarker proﬁles and prognoses were evaluated.  \nResults: LAR (28 .6%) and MES (11 . 2%) were the most and least frequent subtypes. The IHC-TNBC subtypes demonstrated distinct clinicopathological features and biomarker proﬁles, corresponding to the reported features in gene proﬁling studies. IM-inﬂamed subtype had the best outcome, while BLIS had a signiﬁcantly poorer survival. Differential breast-speciﬁc marker expressions were found. Trichorhinophalangeal syndrome type 1 (TRPS1) was more sensitive for IM-inﬂamed and BLIS, GATA-binding protein 3 (GATA3) for IM-excluded and MES, and gross cystic disease ﬂuid protein 15 (GCDFP15) for LAR subtypes.  \nConclusions: Our ﬁndings demonstrated the feasibility of IHC surrogates to stratify TNBC subtypes with distinct features and prognoses. The IM subtype can be reﬁned by its CD8 spatial pattern. Breast-speciﬁc marker expression varied among the subtypes. Marker selection should be tailored accordingly.  \nKey words: triple-negative breast cancers, surrogate subtyping, clinicopathological features, breast markers  \nINTRODUCTION  \nTriple-negative breast cancers (TNBCs), deﬁned as breast cancers without expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), are clinically aggressive and prone to distant metastasis.1 Their triple-negative status poses several challenges in clinical management. They do not respond to routine breast cancer-targeted therapies, rendering patients with TNBC with just a few treatment options. Moreover, it is more difﬁcult to conﬁrm their breast origin due to a lower sensitivity for breast lineage-  \n*Correspondence to: Prof. Gary M. Tse, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Ngan Shing Street, Shatin, NT, Hong Kong, China. Tel: þ852-35052359; Fax: þ852-26374858  \nE-mail: [garytse@cuhk.edu.hk](garytse@cuhk.edu.hk) (G. M. Tse).  \n2059-7029/© 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \nspeciﬁc markers,2,3 thereby complicating their diagnosis ina metastatic setting.  \nTNBC has been increasingly recognized as a heterogeneous cancer group that exhibits substantial differences in genomic and transcriptomic proﬁles. In recent decades, by molecular proﬁling, se","cbCaiq2cH6epMPgb","https://ap.wps.com/l/cbCaiq2cH6epMPgb","pdf",926601,11,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Key words","[{\"question\":\"What TNBC subtypes were evaluated in the study?\",\"answer\":\"The study classified 123 TNBC cases into luminal androgen receptor (LAR), basal-like immunosuppressive (BLIS), mesenchymal-like (MES), and immunomodulatory (IM). The IM group was further divided into IM-excluded and IM-inflamed using CD8 spatial distribution.\"},{\"question\":\"How were TNBC subtypes determined in this research?\",\"answer\":\"TNBC cases were classified using immunohistochemistry (IHC) surrogates based on androgen receptor (AR), CD8, FOXC1, and DCLK1. The work assessed how well this IHC approach captured clinicopathological and biomarker patterns linked to gene-profiling subtypes.\"},{\"question\":\"Which subtype showed the best and poorest outcomes?\",\"answer\":\"The IM-inflamed subtype had the best outcome, whereas BLIS had significantly poorer survival. The IHC-defined subtypes also showed distinct clinicopathological and biomarker profiles.\"}]","Subtyping of triple-negative breast cancers - its prognostication and implications in diagnosis of breast origin | PDF",1790020031,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca3022496e7c376e0bf40502dd1f7a86.webp",983,1269,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5dcd60b79ec70e7b8c42500aff054c5e.webp",982,1268,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb461cd1740db51650cca2563dd8f7af.webp",981,1266,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5d288508a50bae6580595fa64471025.webp",980,1265]